middle.news
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infection Treatment in Indonesia
9:56am on Thursday 25th of September, 2025 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infection Treatment in Indonesia
9:56am on Thursday 25th of September, 2025 AEST
Key Points
Patient dosing underway at five clinical sites in Indonesia
Trial targets enrollment of up to 310 diabetic foot infection patients
Interim analysis planned for Q1 2026 with potential accelerated approval
Indonesia’s diabetes prevalence exceeds 20 million adults, highlighting market opportunity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE